Tezepelumab in Allergic Rhinitis and Asthma Study (TEZARS)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 29, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Asthma With Allergic Rhinitis

Interventions

BIOLOGICAL

Tezepelumab

Tezepelumab is a monoclonal antibody that blocks thymic stromal lymphopoietin (TSLP).

Trial Locations (1)

RECRUITING

Kingston Health Sciences Centre- Kingston General Hospital, Kingston

All Listed Sponsors

lead

Dr. Anne Ellis

OTHER